Trials / Completed
CompletedNCT00333788
Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease
Open Label Long Term Clinical Trial Evaluating Efficacy and Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87042 Study.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 233 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will continue to assess the safety of certolizumab pegol (CDP870) as well as examine the evolution of long term efficacy in Crohn's disease patients who completed study C87042 \[NCT00308581\]. It will also assess the effect of subcutaneous CDP870 400 mg on direct cost parameters.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Certolizumab pegol (CDP870) | 400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks |
Timeline
- Start date
- 2006-10-01
- Primary completion
- 2010-04-01
- Completion
- 2010-04-01
- First posted
- 2006-06-06
- Last updated
- 2018-08-07
- Results posted
- 2011-07-12
Locations
65 sites across 12 countries: United States, Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00333788. Inclusion in this directory is not an endorsement.